These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28064163)

  • 21. Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
    Jin SM; Han KA; Yu JM; Sohn TS; Choi SH; Chung CH; Park IeB; Rhee EJ; Baik SH; Park TS; Lee IK; Ko SH; Hwang YC; Cha BS; Lee HW; Nam MS; Lee MK
    Arterioscler Thromb Vasc Biol; 2016 Oct; 36(10):2108-14. PubMed ID: 27493100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Spironolactone Add-on for Preventing or Slowing the Progression of Diabetic Nephropathy: A Meta-analysis.
    Hou J; Xiong W; Cao L; Wen X; Li A
    Clin Ther; 2015 Sep; 37(9):2086-2103.e10. PubMed ID: 26254276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial.
    Lindhardt M; Persson F; Currie G; Pontillo C; Beige J; Delles C; von der Leyen H; Mischak H; Navis G; Noutsou M; Ortiz A; Ruggenenti PL; Rychlik I; Spasovski G; Rossing P
    BMJ Open; 2016 Mar; 6(3):e010310. PubMed ID: 26936907
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The urinary proteomics classifier chronic kidney disease 273 predicts cardiovascular outcome in patients with chronic kidney disease.
    Verbeke F; Siwy J; Van Biesen W; Mischak H; Pletinck A; Schepers E; Neirynck N; Magalhães P; Pejchinovski M; Pontillo C; Lichtinghagen R; Brand K; Vlahou A; De Bacquer D; Glorieux G
    Nephrol Dial Transplant; 2021 Apr; 36(5):811-818. PubMed ID: 31837226
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.
    de Zeeuw D; Agarwal R; Amdahl M; Audhya P; Coyne D; Garimella T; Parving HH; Pritchett Y; Remuzzi G; Ritz E; Andress D
    Lancet; 2010 Nov; 376(9752):1543-51. PubMed ID: 21055801
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best?
    Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B
    Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors.
    Davidson MB; Wong A; Hamrahian AH; Stevens M; Siraj ES
    Endocr Pract; 2008 Nov; 14(8):985-92. PubMed ID: 19095597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria.
    Oellgaard J; Gæde P; Persson F; Rossing P; Parving HH; Pedersen O
    J Diabetes Complications; 2018 Dec; 32(12):1133-1140. PubMed ID: 30282584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S; Maruyama S; Makino H; Wada J; Ogawa D; Uzu T; Araki H; Koya D; Kanasaki K; Oiso Y; Goto M; Nishiyama A; Kobori H; Imai E; Ando M; Matsuo S
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-dose spironolactone, added to long-term ACE inhibitor therapy, reduces blood pressure and urinary albumin excretion in obese patients with hypertensive target organ damage.
    Bomback AS; Muskala P; Bald E; Chwatko G; Nowicki M
    Clin Nephrol; 2009 Dec; 72(6):449-56. PubMed ID: 19954722
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study.
    Nielsen SE; Persson F; Frandsen E; Sugaya T; Hess G; Zdunek D; Shjoedt KJ; Parving HH; Rossing P
    Diabet Med; 2012 Aug; 29(8):e184-90. PubMed ID: 22268920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effects of Direct Renin Inhibitor and Angiotensin Receptor Blocker on Albuminuria in Hypertensive Patients with Type 2 Diabetes. A Randomized Controlled Trial.
    Uzu T; Araki SI; Kashiwagi A; Haneda M; Koya D; Yokoyama H; Kida Y; Ikebuchi M; Nakamura T; Nishimura M; Takahara N; Obata T; Omichi N; Sakamoto K; Shingu R; Taki H; Nagai Y; Tokuda H; Kitada M; Misawa M; Nishiyama A; Kobori H; Maegawa H;
    PLoS One; 2016; 11(12):e0164936. PubMed ID: 28033332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of addition of silymarin to renin-angiotensin system inhibitors on proteinuria in type 2 diabetic patients with overt nephropathy: a randomized, double-blind, placebo-controlled trial.
    Fallahzadeh MK; Dormanesh B; Sagheb MM; Roozbeh J; Vessal G; Pakfetrat M; Daneshbod Y; Kamali-Sarvestani E; Lankarani KB
    Am J Kidney Dis; 2012 Dec; 60(6):896-903. PubMed ID: 22770926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial.
    Oxlund CS; Henriksen JE; Tarnow L; Schousboe K; Gram J; Jacobsen IA
    J Hypertens; 2013 Oct; 31(10):2094-102. PubMed ID: 24107738
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD).
    Andress DL; Coll B; Pritchett Y; Brennan J; Molitch M; Kohan DE
    Life Sci; 2012 Oct; 91(13-14):739-42. PubMed ID: 22326504
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAIT-survey-Prevalence of albuminuria in patients with diabetes and hypertension in Turkey.
    Fici F; Bakir EA; Beyaz S; Makel W; Robles NR
    Prim Care Diabetes; 2018 Dec; 12(6):558-564. PubMed ID: 30327190
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Beneficial impact of spironolactone in diabetic nephropathy.
    Schjoedt KJ; Rossing K; Juhl TR; Boomsma F; Rossing P; Tarnow L; Parving HH
    Kidney Int; 2005 Dec; 68(6):2829-36. PubMed ID: 16316360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The mineralocorticoid receptor blocker spironolactone lowers plasma interferon-γ and interleukin-6 in patients with type 2 diabetes and treatment-resistant hypertension.
    Thangaraj SS; Oxlund CS; Fonseca MPD; Svenningsen P; Stubbe J; Palarasah Y; Ketelhuth DFJ; Jacobsen IA; Jensen BL
    J Hypertens; 2022 Jan; 40(1):153-162. PubMed ID: 34843183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.